1 January 2025 v2026.39.1 micro_entity_frs_105_v1_1_3 filingSoftwarefalsetrue19 October 2026truetruetruefalseNo description of principal activitytruexbrli:purexbrli:sharesiso4217:GBP070205292025-01-012025-12-31070205292025-12-31070205292024-12-3107020529core:WithinOneYear2025-12-3107020529core:WithinOneYear2024-12-3107020529bus:RegisteredOffice2025-01-012025-12-31070205292024-01-012024-12-3107020529bus:Director12025-01-012025-12-310702052912025-01-012025-12-3107020529countries:EnglandWales2025-01-012025-12-3107020529bus:AuditExemptWithAccountantsReport2025-01-012025-12-3107020529bus:PrivateLimitedCompanyLtd2025-01-012025-12-3107020529bus:Micro-entities2025-01-012025-12-3107020529bus:FullAccounts2025-01-012025-12-31
Company registration number:
07020529
Medexpress Ltd
Revised Unaudited Filleted Financial Statements for the year ended
31 December 2025
Medexpress Ltd
Statement of Financial Position
31 December 2025
20252024
££
Fixed assets
284,466
 
226,098
 
   
Current assets
621,647
 
604,313
 
Creditors: amounts falling due within one year
(196,617
 )
(236,420
 )
Net current assets
425,030
 
367,893
 
Total assets less current liabilities
709,496
 
593,991
 
   
Capital and reserves
709,496
 
593,991
 

Notes to the Financial Statements

1 General information

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is
43 Warboys Road
,
Old Hurst
,
Huntingdon
,
Cambridgeshire
,
PE28 3AG
, England.

2 Average number of employees

The average number of persons employed by the company during the year was
18
(2024:
18.00
).

3 Revised financial statements

These revised financial statements replace the original financial statements for the year ended
31 December 2025
.
They are now the statutory financial statements for that year.
They have been prepared as at
31 December 2025
and not as at the date of revision and accordingly do not deal with the events between those dates.
The financial statements have been revised to correct the accounting treatment of certain balances identified following a subsequent review of the company's accounting records. The revisions principally relate to: the impairment of trade receivables which were considered to be irrecoverable at the reporting date; and the recognition of accrued income which, following review, was determined not to meet the criteria for recognition at 31 December 2025. The revised financial statements have been prepared as if the revisions had been made at the date on which the original financial statements were approved. The effect of these revisions has been to reduce profit before taxation by £125,770 and reduce net assets by the corresponding post-tax effect.
That £125,770 comprises: trade debtor impairment: £70,770 reversal/reduction of accrued income: £55,000 total P&L adjustment: £125,770.
For the year ending
31 December 2025
, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
  • The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
  • The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared in accordance with the micro-entity provisions and have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.
These revised financial statements were approved by the
board of directors
and authorised for issue on
19 October 2026
, and are signed on behalf of the board by:
R Allan
Director
Company registration number:
07020529